 |
|
Treat HIV-1 Infection Like Other Infections—Treat It
Bruce D. Walker, MD;
Nesli Basgoz, MD
JAMA. 1998;280:91-93.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
TREMENDOUS ADVANCES in the development of effective antiretroviral therapy for human immunodeficiency virus 1 (HIV-1) infection have been associated with an ongoing debate regarding when to initiate antiretroviral therapy.1-2 Although the concept of delayed therapy is somewhat foreign to the field of infectious diseases, it has been supported by concerns about the long-term benefits of therapies currently available, the rigors of the currently available regimens, and the typically slow course of disease in persons with HIV-1 infection. Advances in treatment have been paralleled by recent advances in the understanding of HIV-1 pathogenesis, which provide important new insights as to how the virus is affected by immune selection pressure and why antiviral drug resistance is so prevalent. In our opinion, currently available data provide convincing arguments for initiation of therapy at the earliest possible juncture in persons who are not controlling viremia on their . . . [Full Text of this Article]
From the Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, Mass.
RELATED ARTICLE
The Case for Conservative Management of Early HIV Disease
William J. Burman, Randall R. Reves, and David L. Cohn
JAMA. 1998;280(1):93-95.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
When should antiretroviral therapy for HIV be started?
Phillips et al.
BMJ 2007;334:76-78.
FULL TEXT
Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata
Palella et al.
ANN INTERN MED 2003;138:620-626.
ABSTRACT
| FULL TEXT
Gay Men and HIV/AIDS Risk Management
Flowers
Health (London) 2001;5:50-75.
ABSTRACT
|
